Detalhe da pesquisa
1.
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
Int J Med Sci;
18(10): 2245-2250, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33859534
2.
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Front Oncol;
13: 1152123, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37260975
3.
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.
Ther Adv Med Oncol;
13: 17588359211059873, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35173816